Brief: Valneva H1 Adjusted EBITDA Negative EUR 6 Mln
12/08/2025 06:04
Aug 12 (Reuters) - Valneva SE VLS.PA: H1 ADJUSTED EBITDA EUR -6 MILLION H1 NET INCOME EUR -20.8 MILLION H1 REVENUE EUR 97.6 MILLION 2025 FINANCIAL OUTLOOK CONFIRMED CASH AND CASH EQUIVALENTS OF EUR 161.3 MILLION AT END OF JUNE 2025 EXPECTS THAT THIRD-PARTY SALES WILL GRADUALLY WIND DOWN TO LESS THAN 5% OF ITS TOTAL SALES BY 2026/2027 Source text: ID:nGNEbl4tWB Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency